PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
PTC Therapeutics (PTCT) Misses Q2 EPS by 76c
August 4, 2022 5:15 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($2.13), $0.76 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $166 million versus the consensus estimate of $162.12 million.
GUIDANCE:
PTC Therapeutics sees Q3 2022 revenue of $700-750 million, versus the consensus... More
